Trials / Not Yet Recruiting
Not Yet RecruitingNCT07196111
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
Evaluation of the Safety and Efficacy of BAFFR CAR-T Therapy in Clinical Studies for Recurrent/Refractory B Cell Tumors.
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.
Detailed description
This study is a single-arm, mult-center clinical trial of dose escalation and dose expansion, primarily aimed at evaluating the safety, tolerability, and preliminary efficacy of BAFFR CAR-T cell infusion in subjects with relapsed/refractory B-cell tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BAFFR CAR-T | A single infusion of BAFFR CAR-T Injection administered intravenously. |
Timeline
- Start date
- 2025-10-10
- Primary completion
- 2028-10-09
- Completion
- 2028-12-09
- First posted
- 2025-09-29
- Last updated
- 2025-09-29
Source: ClinicalTrials.gov record NCT07196111. Inclusion in this directory is not an endorsement.